Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT02858726 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Uremic Pruritus

Interventions

DRUG: CR845 0.5 mcg/kg
DRUG: CR845 1 mcg/kg
DRUG: CR845 1.5mcg/kg
DRUG: Placebo

Sponsor

Cara Therapeutics, Inc.